November 4, 2025 — Leads & Copy —
Niagen Bioscience, Inc. (NASDAQ:NAGE) reported its third-quarter 2025 financial results, showcasing a 33% increase in total net sales to $34.0 million. Tru Niagen® sales rose by 44% to $26.0 million, and net income reached $4.6 million, or $0.06 earnings per share, up from $1.9 million, or $0.02 earnings per share, in the prior year quarter.
Gross margin increased to 64.5%, and sales and marketing expenses improved to 25.8% of net sales. Adjusted EBITDA, a non-GAAP measure, surged by 120% to $6.4 million. The company reaffirmed its full-year 2025 net sales growth outlook between 25% and 30%, driven by Tru Niagen® and Niagen® ingredients momentum.
Recent operational highlights include the launch of AboutNAD®, an online platform for NAD+ research, a successful challenge against false NAD+ product claims, and the expansion of the pharmaceutical-grade Niagen Plus™ distribution network to over 1,000 clinics. A live webcast to discuss the results will be held on November 4, 2025, at 4:30 p.m. Eastern Standard Time.
Niagen Bioscience CEO Rob Fried said the company delivered another strong performance with third quarter net sales of $34.0 million, up 33% year-over-year, and $4.6 million in net income.”
Contact:
Niagen Bioscience CEO Rob Fried
Source: Niagen Bioscience, Inc.
